|788.75||-29.85||-3.65%||Vol 300||1Y Perf 64.25%|
|Sep 13th, 2021 18:40 DELAYED|
|- -%||- -|
|Target Price||-||Analyst Rating||— — 0.00|
|Potential %||-||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★★ 69.47|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 84.04|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||91.18||Earnings Rating||Buy|
|Market Cap||23.48B||Earnings Date||4th Nov 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Nov 2021|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||640|
|Avg. Monthly Volume||405|
|Avg. Quarterly Volume||567|
Bio-Rad Laboratories Inc. Class B (NYSE: BIO.B) stock closed at 788.75 per share at the end of the most recent trading day (a -3.65% change compared to the prior day closing price) with a volume of 300.0000 shares and market capitalization of 23.48B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 8000 people. Bio-Rad Laboratories Inc. Class B CEO is Norman Schwartz.
The one-year performance of Bio-Rad Laboratories Inc. Class B stock is 64.25%, while year-to-date (YTD) performance is 37.38%. BIO.B stock has a five-year performance of 390.73%. Its 52-week range is between 480.2 and 818.6, which gives BIO.B stock a 52-week price range ratio of 91.18%
Bio-Rad Laboratories Inc. Class B currently has a PE ratio of 5.90, a price-to-book (PB) ratio of 2.03, a price-to-sale (PS) ratio of 1.39, a price to cashflow ratio of 34.60, a PEG ratio of 2.32, a ROA of 31.39%, a ROC of 40.75% and a ROE of 41.80%. The company’s profit margin is 84.36%, its EBITDA margin is 186.30%, and its revenue ttm is $2.88 Billion , which makes it $568.15 revenue per share.
Of the last four earnings reports from Bio-Rad Laboratories Inc. Class B, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Bio-Rad Laboratories Inc. Class B’s next earnings report date is 04th Nov 2021.
The consensus rating of Wall Street analysts for Bio-Rad Laboratories Inc. Class B is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Bio-Rad Laboratories Inc. Class B stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bio-Rad Laboratories Inc. Class B has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Bio-Rad Laboratories Inc. Class B has a Buy technical analysis rating based on Technical Indicators (ADX : 83.45, ATR14 : 13.62, CCI20 : 44.24, Chaikin Money Flow : 0.58, MACD : 14.52, Money Flow Index : 25.85, ROC : 3.40, RSI : 43.77, STOCH (14,3) : 47.95, STOCH RSI : 1.00, UO : 10.28, Williams %R : -52.05), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bio-Rad Laboratories Inc. Class B in the last 12-months were: Ajit Ramalingam (Option Excercise at a value of $0), Andrew J. Last (Option Excercise at a value of $598 480), Andrew J. Last (Sold 2 000 shares of value $1 626 203 ), Annette Tumolo (Option Excercise at a value of $191 184), Annette Tumolo (Sold 1 800 shares of value $1 244 413 ), Dara Wright (Option Excercise at a value of $0), Ilan Daskal (Option Excercise at a value of $716 898), Ilan Daskal (Sold 3 110 shares of value $2 397 778 ), Michael Crowley (Option Excercise at a value of $418 680), Michael Crowley (Sold 3 374 shares of value $2 481 966 ), Norman Schwartz (Option Excercise at a value of $3 702 220), Timothy S. Ernst (Option Excercise at a value of $63 728), Timothy S. Ernst (Sold 1 446 shares of value $965 649 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.